We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

To Yield Further Information On The Efficacy And Safety Of Viagra Among Subjects With Arterial Hypertension .

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: September 8, 2005
Last Update Posted: December 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
To assess changes with respect to Erectile Dysfunction in subjects treated with Viagra and antihypertensive therapy.

Condition Intervention Phase
Impotence Hypertension Drug: Sildenafil Citrate Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Multicenter, Non Comparative Study, To Confirm The Efficacy And Tolerability Of Viagra In Subjects With Erectile Dysfunction And Arterial Hypertension Who Are Taking Antihypertensive Treatment.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The primary efficacy measure is the percent of ITT subjects at week 8 with positive response to the Global Efficacy Assessment question regarding the effectiveness of the medication in improving erections over no treatment at all for ED.

Secondary Outcome Measures:
  • The evaluation of change from baseline to week 8 on the toal SHI-M (Sexual Health Inventory-Male) score and the 5 individual items on the SHI-M. Global Efficacy Assessment Questions 2 and 3 at week 8.

Estimated Enrollment: 253
Study Start Date: March 2005
Estimated Study Completion Date: November 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with arterial hypertension treated with one or more antihypertensive agents, the doses of which have been stable for at least 4 weeks prior to the baseline visit, with a documented clinical diagnosis of ED and a confirmation of this by a qualification of 21 or less on the SHI-M.

Exclusion Criteria:

  • Subjects with resting sitting systolic blood pressure >170 or <110mmHg or resting sitting diastolic blood pressure >90 or <50mmHg, with significant cardiovascular disease and retinitis pigmentosa, treatment with nitrates, alfablockers or CYP3A4 inhibitors.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00150358

Pfizer Investigational Site
Torreon, Coahuila, Mexico, 72000
Pfizer Investigational Site
Mexico, DF, Mexico, 07760
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico, 44290
Pfizer Investigational Site
Colonia Centro, Mexico City, Mexico, 06090
Pfizer Investigational Site
DF, Mexico City, Mexico, 06760
Pfizer Investigational Site
Monterrey, Nuevo Leon, Mexico, 64000
Pfizer Investigational Site
Monterrey, Nuevo Leon, Mexico, 64460
Pfizer Investigational Site
Merida, Yucatan, Mexico, 97070
Pfizer Investigational Site
Aguascalientes, Mexico, C.P. 20230
Pfizer Investigational Site
Chihuahua, Mexico, 31238
Pfizer Investigational Site
Durango, Mexico, 34300
Pfizer Investigational Site
Metepec, Mexico, 52140
Pfizer Investigational Site
Puebla, Mexico, 72090
Pfizer Investigational Site
San Luis Potosi, Mexico, 78090
Pfizer Investigational Site
San Luis Potosí, Mexico, 78240
Pfizer Investigational Site
Veracruz, Mexico, C.P. 97897
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

ClinicalTrials.gov Identifier: NCT00150358     History of Changes
Other Study ID Numbers: A1481187
First Submitted: September 6, 2005
First Posted: September 8, 2005
Last Update Posted: December 11, 2006
Last Verified: December 2006

Additional relevant MeSH terms:
Erectile Dysfunction
Vascular Diseases
Cardiovascular Diseases
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents